SG11202003806WA - Novel compounds for use in treating depression and migraine - Google Patents
Novel compounds for use in treating depression and migraineInfo
- Publication number
- SG11202003806WA SG11202003806WA SG11202003806WA SG11202003806WA SG11202003806WA SG 11202003806W A SG11202003806W A SG 11202003806WA SG 11202003806W A SG11202003806W A SG 11202003806WA SG 11202003806W A SG11202003806W A SG 11202003806WA SG 11202003806W A SG11202003806W A SG 11202003806WA
- Authority
- SG
- Singapore
- Prior art keywords
- migraine
- novel compounds
- treating depression
- depression
- treating
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203136 | 2017-11-22 | ||
| PCT/EP2018/082143 WO2019101825A1 (en) | 2017-11-22 | 2018-11-22 | Novel compounds for use in treating depression and migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003806WA true SG11202003806WA (en) | 2020-06-29 |
Family
ID=60569579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003806WA SG11202003806WA (en) | 2017-11-22 | 2018-11-22 | Novel compounds for use in treating depression and migraine |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11357767B2 (en) |
| EP (1) | EP3713563A1 (en) |
| JP (1) | JP7405484B2 (en) |
| KR (1) | KR20200090816A (en) |
| CN (1) | CN111372582A (en) |
| AU (1) | AU2018371152B2 (en) |
| BR (1) | BR112020010207A2 (en) |
| CA (1) | CA3079481A1 (en) |
| IL (1) | IL274822B2 (en) |
| SG (1) | SG11202003806WA (en) |
| WO (1) | WO2019101825A1 (en) |
| ZA (1) | ZA202002101B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2959243T3 (en) * | 2017-04-05 | 2024-02-22 | Khondrion Ip B V | New treatment for mitochondrial diseases |
| US11672787B2 (en) * | 2017-11-22 | 2023-06-13 | Khondrion Ip B.V. | Compounds as mPGES-1 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001048784A (en) | 1999-08-11 | 2001-02-20 | Takeda Chem Ind Ltd | Activator for mitochondrial function |
| JP5098051B2 (en) | 2007-04-05 | 2012-12-12 | Ｓｂｉファーマ株式会社 | Mitochondrial disorder brain disease therapeutic agent and diagnostic agent |
| US20090281112A1 (en) * | 2008-05-08 | 2009-11-12 | Fabre-Kramer Pharmaceuticals, Inc. | Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders |
| US10058612B2 (en) | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
| LT2872497T (en) * | 2012-07-12 | 2017-04-25 | Khondrion Ip B.V. | Chromanyl derivatives for treating mitochondrial disease |
| MX364547B (en) * | 2012-07-12 | 2019-04-30 | Khondrion Ip B V | Chromanyl derivatives for treating mitochondrial disease. |
| US10815211B2 (en) * | 2015-10-08 | 2020-10-27 | Khondrion Ip B.V. | Compounds for treating mitochondrial disease |
-
2018
- 2018-11-22 KR KR1020207017138A patent/KR20200090816A/en not_active Application Discontinuation
- 2018-11-22 US US16/765,480 patent/US11357767B2/en active Active
- 2018-11-22 AU AU2018371152A patent/AU2018371152B2/en active Active
- 2018-11-22 IL IL274822A patent/IL274822B2/en unknown
- 2018-11-22 JP JP2020526089A patent/JP7405484B2/en active Active
- 2018-11-22 CA CA3079481A patent/CA3079481A1/en active Pending
- 2018-11-22 CN CN201880075582.6A patent/CN111372582A/en active Pending
- 2018-11-22 SG SG11202003806WA patent/SG11202003806WA/en unknown
- 2018-11-22 BR BR112020010207-5A patent/BR112020010207A2/en unknown
- 2018-11-22 WO PCT/EP2018/082143 patent/WO2019101825A1/en unknown
- 2018-11-22 EP EP18804003.4A patent/EP3713563A1/en active Pending
-
2020
- 2020-05-04 ZA ZA2020/02101A patent/ZA202002101B/en unknown
-
2022
- 2022-05-12 US US17/742,417 patent/US20220273636A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200289491A1 (en) | 2020-09-17 |
| CN111372582A (en) | 2020-07-03 |
| AU2018371152A1 (en) | 2020-06-04 |
| WO2019101825A1 (en) | 2019-05-31 |
| US11357767B2 (en) | 2022-06-14 |
| EP3713563A1 (en) | 2020-09-30 |
| US20220273636A1 (en) | 2022-09-01 |
| ZA202002101B (en) | 2021-04-28 |
| IL274822B2 (en) | 2024-03-01 |
| KR20200090816A (en) | 2020-07-29 |
| IL274822A (en) | 2020-07-30 |
| RU2020120239A (en) | 2021-12-22 |
| CA3079481A1 (en) | 2019-05-31 |
| AU2018371152B2 (en) | 2024-02-08 |
| JP2021504305A (en) | 2021-02-15 |
| IL274822B1 (en) | 2023-11-01 |
| BR112020010207A2 (en) | 2020-10-13 |
| JP7405484B2 (en) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1252937A1 (en) | Methods and kits for treating depression | |
| IL272596A (en) | Pridopidine for use in treating als | |
| IL251759B (en) | Compositions and methods for treating insomnia | |
| IL269490B (en) | Surface treatment methods and compositions therefor | |
| ZA201906236B (en) | Kits and methods for treating hair | |
| GB201710906D0 (en) | Compounds and methods for treating peripheral neuropathy | |
| PL3558280T3 (en) | Migraine prevention and treatment | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| IL271020A (en) | Tinostamustine for use in treating sarcoma | |
| EP3519058C0 (en) | Compositions and methods for treating hair | |
| HK1258825A1 (en) | Methods and compositions for treating hyperhidrosis | |
| PL3402575T4 (en) | Methods and compositions for treating damaged hair | |
| IL271728A (en) | Agents, uses and methods for treatment | |
| IL291266A (en) | Compositions and methods for treating infections | |
| IL271923A (en) | Methods and compositions for treating addictions | |
| PL3386527T3 (en) | Compositions for use in treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine | |
| IL274822A (en) | Novel compounds for use in treating depression and migraine | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| IL271211B1 (en) | Acetyl-leucine for use in treatment of migraine | |
| IL271758A (en) | Statin compositions and methods for use in treating synucleinopathies | |
| IL272945A (en) | Topical compositions and methods for treatment | |
| GB2560769B (en) | Compounds and compositions for use in treating psoriasis | |
| PL3528811T3 (en) | Vortioxetine and mao inhibitors for treating depression | |
| GB201709464D0 (en) | Process and composition |